Analyzing Neurocrine Biosciences (NBIX) and Its Peers

Neurocrine Biosciences (NASDAQ: NBIX) is one of 296 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its competitors? We will compare Neurocrine Biosciences to similar businesses based on the strength of its analyst recommendations, profitability, institutional ownership, earnings, valuation, dividends and risk.

Insider & Institutional Ownership

50.4% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 4.8% of Neurocrine Biosciences shares are owned by company insiders. Comparatively, 16.4% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Neurocrine Biosciences and its competitors top-line revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Neurocrine Biosciences $6.34 million -$219.96 million -24.65
Neurocrine Biosciences Competitors $263.26 million $68.25 million -6.44

Neurocrine Biosciences’ competitors have higher revenue and earnings than Neurocrine Biosciences. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Risk & Volatility

Neurocrine Biosciences has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500. Comparatively, Neurocrine Biosciences’ competitors have a beta of 6.62, meaning that their average share price is 562% more volatile than the S&P 500.


This table compares Neurocrine Biosciences and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Neurocrine Biosciences N/A -69.86% -48.65%
Neurocrine Biosciences Competitors -5,486.48% -451.59% -42.57%

Analyst Recommendations

This is a summary of current ratings and recommmendations for Neurocrine Biosciences and its competitors, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neurocrine Biosciences 0 1 16 0 2.94
Neurocrine Biosciences Competitors 766 3047 11235 227 2.72

Neurocrine Biosciences presently has a consensus target price of $69.31, suggesting a potential upside of 11.60%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 36.02%. Given Neurocrine Biosciences’ competitors higher possible upside, analysts clearly believe Neurocrine Biosciences has less favorable growth aspects than its competitors.


Neurocrine Biosciences competitors beat Neurocrine Biosciences on 8 of the 12 factors compared.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc. is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease. Its product pipeline also includes NBI-640756, which targets tremor and NBI-74788, which targets classic congenital adrenal hyperplasia. Its R&D focus is on addressing diseases and disorders of the central nervous and endocrine systems.

What are top analysts saying about Neurocrine Biosciences Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Neurocrine Biosciences Inc. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit